Arexvy, which was initially approved by the FDA in May 2023 for administration in adults over 60, has been granted priority review in the U.S. for use in adults ages 50-59.
If approved, it will become the first RSV vaccine available for the age group, according to a Feb. 6 news release.
The FDA is slated to make a decision on the drug’s approval for the new age group by June 7.
